|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2007-3-30
|
|
pubmed:abstractText |
Taste alterations (dysgeusia) are well described in head and neck cancer patients who undergo radiotherapy (RT). Anecdotal observations and pilot studies have suggested zinc may mitigate these symptoms. This multi-institutional, double-blind, placebo-controlled trial was conducted to provide definitive evidence of this mineral's palliative efficacy.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
0360-3016
|
|
pubmed:author |
pubmed-author:AthertonPamela JPJ,
pubmed-author:BeardenJames DJD3rd,
pubmed-author:HalyardMichele YMY,
pubmed-author:JatoiAminahA,
pubmed-author:LoprinziCharles LCL,
pubmed-author:PerezEdith AEA,
pubmed-author:SloanJeff AJA,
pubmed-author:SooriGammiG,
pubmed-author:StellaPhilip JPJ,
pubmed-author:VoraSujay ASA,
pubmed-author:ZalduendoAnthony CAC,
pubmed-author:ZhuAngelaA
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
67
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1318-22
|
|
pubmed:dateRevised |
2007-12-3
|
|
pubmed:meshHeading |
pubmed-meshheading:17394940-Administration, Oral,
pubmed-meshheading:17394940-Adult,
pubmed-meshheading:17394940-Aged,
pubmed-meshheading:17394940-Aged, 80 and over,
pubmed-meshheading:17394940-Double-Blind Method,
pubmed-meshheading:17394940-Drug Administration Schedule,
pubmed-meshheading:17394940-Female,
pubmed-meshheading:17394940-Head and Neck Neoplasms,
pubmed-meshheading:17394940-Humans,
pubmed-meshheading:17394940-Male,
pubmed-meshheading:17394940-Middle Aged,
pubmed-meshheading:17394940-Taste Disorders,
pubmed-meshheading:17394940-Treatment Outcome,
pubmed-meshheading:17394940-Zinc Sulfate
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Does zinc sulfate prevent therapy-induced taste alterations in head and neck cancer patients? Results of phase III double-blind, placebo-controlled trial from the North Central Cancer Treatment Group (N01C4).
|
|
pubmed:affiliation |
Mayo Clinic, Scottsdale, AZ, USA.
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Multicenter Study,
Clinical Trial, Phase III,
Research Support, N.I.H., Extramural
|
